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IDENTIFICATION OF SMALL MOLECULE MODULATORS OF THE HIPPO 
TUMOR SUPPRESSOR PATHWAY 
HATIM M MUSTALY 
ABSTRACT 
The Hippo signaling pathway, originally identified in Drosophila 
melanogaster and later shown to be conserved in mammals, is essential in 
regulating organ size and maintaining tissue homeostasis. It is now clear that 
functional inactivation of the Hippo pathway is common in variety of cancers and 
promotes their development and progression. This suggests re-activation of 
Hippo pathway activity may prove an effective anti-cancer therapy. Here, we 
describe two small molecule activators of the Hippo pathway that we have 
recently uncovered from a focused small-molecule inhibitor screen.  
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INTRODUCTION 
The Hippo signaling pathway is a recently emerging growth control 
pathway which was first discovered in Drosophila melanogaster and later shown 
to be conserved in humans. There has been growing interest in studying the 
Hippo pathway as a result of several studies indicating that Hippo signaling may 
play a fundamental role in organ growth control, stem cell functions and limiting 
tumorigenesis (Zhao, B et al., 2008). Indeed, the Hippo pathway has been shown 
to be inactivated in a wide variety of cancers, suggesting that Hippo signaling 
may play an important role in preventing tumor initiation and progression (Pan, 
D., 2010; Johnson, R & Halder, G., 2013; Yu, F & Guan, K., 2013). Hence, there 
has been widespread excitement and speculation about developing therapeutics 
that reactivate Hippo pathway components in order to treat the diverse types of 
cancers. 
Components of the Hippo Pathway 
The Hippo pathway consists of a serine-threonine kinase module and a 
transcriptional module. The kinase module includes mammalian MST1 and MST 
2 (STE-20 like protein kinases 1 & 2) and LATS-1 and LATS-2 (large tumor 
suppressor kinases 1 & 2) (Moroishi, T et al., 2015; Pan D., 2010) (Fig 1). The 
transcriptional module includes the transcriptional co-factors YAP (yes-
associated protein) and TAZ (transcriptional co-activator with PDZ-binding motif).  
The Hippo pathway exists to regulate YAP and TAZ, which bind the transcription 
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factor TEAD and promote transcription of genes important for proliferation and 
cell survival. YAP and TAZ are the main proteins which modulate signaling in the 
Hippo pathway (Zhao B et al., 2008; Moroishi, T et al., 2015). 
YAP and TAZ exert their effects on transcription (are regulated by the 
cellular localization) by translocating between the nucleus and the cytoplasm. 
When the Hippo pathway is “off” (Fig 1b), YAP/TAZ are not phosphorylated. As a 
result, they translocate into the nucleus and induce expression of cell-
proliferative genes such as Cyclin E and anti-apoptotic genes such as IAP 
(inhibitor of apoptosis proteins) (Harvey, L et al 2013). By contrast, when the 
Hippo pathway is “on” (Fig 1a), MST 1 and MST 2 as well as LATS1 and LATS2 
are phosphorylated and activated and they in turn phosphorylate YAP and TAZ. 
Phosphorylation of YAP leads to the creation of a 14-3-3 binding site. 
Consequently, p-YAP binds 14-3-3 and is retained in the cytoplasm where 14-3-3 
is localized. This cytoplasmic localization of YAP and TAZ induces a spatial 
separation of YAP/TAZ from their nuclear target transcription factors and target 
gene promoters (Zhao, B et al., 2010). In addition, YAP phosphorylation also 
leads to β-transducin repeat-containing E3 ubiquitin protein ligase (β-TRCP)-
dependent degradation by the proteasome (Johnson, R & Halder, G., 2013; 
Moroishi, T et al., 2015). Instead of TEAD binding to YAP and TAZ, it complexes 
with the corepressor vestigial like protein (VGL 4), which decreases YAP/TAZ 
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activity and causes a decrease in output of growth-promoting gene products 
(Moroishi, T et al., 2015).  
Role of the Hippo Pathway in Cancer 
Emerging evidence has revealed that the Hippo pathway is functionally 
inactivated in many human cancers. Deregulation of the Hippo pathway and an 
increase in YAP activity have been shown to be prevalent in human carcinomas 
including lung, colorectal, ovarian, liver and prostate cancers (Harvey, F et al., 
2013; Zhao, B et al., 2007; Steinhardt, A et al., 2008) and often correlates with 
poor patient prognosis (Zhang, X et al., 2011; Xu, M et al., 2009). The exact 
mechanism of Hippo pathway inactivation is not well established; however, about 
50% of breast cancers & 60%-70% of astrocytomas have hypermethylated 
LATS1/2 promoter regions that limit expression of the genes (Takashi, Y et al., 
2005; Jiang, Z et al., 2006). In 37% of soft tissue sarcomas and 20% of 
sarcomas, the MST1/2 promoter regions are also shown to be hypermethylated 
(Siedel, C et al., 2007). Additionally, YAP amplification is also observed from the 
11q22 amplicon (Overholtzer, M et al 2006). These results suggest that down 
regulation of Hippo signaling via epigenetic silencing of key activators or 
amplification of YAP correlate with various lethal cancers. Hence, re-activating 
the Hippo pathway provides an attractive therapeutic avenue.  
Uncontrolled cell proliferation, one of the hallmarks of neoplasia, is 
observed following inactivation of proteins in the Hippo pathway (Harvey, F et al., 
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2013). Therefore, reactivating the Hippo pathway could provide an important way 
to control cancer cell growth. In knockdown studies of Hippo pathway 
components, especially MST1/2 knockdowns, the mutant cells proliferated faster 
than the wild type cells and continued to proliferate even after achieving contact 
inhibition (Song, H et al., 2010; Johnson, R & Halder, G., 2014).  In mouse 
models, specific activation of YAP leads to an increase in cell proliferation 
causing organ overgrowth and tumorigenesis (Zhao, B et al., 2008). Increased 
cell proliferation is observed in a variety of developing murine tissues, suggesting 
that YAP has a broadly relevant role in controlling the proliferation of mammalian 
cells (Camargo, F et al., 2007). Human cell culture models also support the 
model where overexpression of YAP or TEAD leads to an increase in cell 
proliferation (Ota, M & Sasaki, H., 2008). 
Deregulation of the Hippo pathway also leads to suppression of apoptosis 
and thereby causes tissue overgrowth (Tapon, N et al., 2002). In Drosophila. 
melanogaster, apoptosis is prevented by expression of IAP1. In mouse models, 
YAP overexpression blocks FAS induced apoptosis and MST1/2 knockdown also 
leads to resistance to apoptosis (Harvey, K et al., 2013; Camargo, F et al., 2007; 
O’Neil, E & Kolch, W., 2003). Furthermore, in human cell culture, YAP activation 
has been shown to increase the level of anti-apoptotic proteins such as IAP1 
(Dong, J et al., 2007). 
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Deregulation of Cell Differentiation 
Components of the Hippo pathway play a critical role in cellular 
differentiation. Numerous studies have revealed that deregulation of Hippo 
pathway or YAP overexpression leads to increased proliferation and a decrease 
in cellular differentiation. In knockout mice, an increased level of YAP and TAZ is 
known to increase tissue specific stem cells and a blockage of cell differentiation 
(Camargo, F et al., 2007). YAP and TAZ are also known to be important in 
mesenchymal stem cells (MSC) differentiation. YAP and TAZ knockout in MSC’s 
show an overall decrease in osteogenesis demonstrating that Hippo components 
are important in cell differentiation. In addition, YAP and TAZ expression have 
also been implicated in myogenesis (Yu, X & Guan, K., 2013). These results 
together suggest that the Hippo pathway plays an important role in cellular 
differentiation and the stem cells involved have a proliferative potential which 
may contribute to cancer development. 
Role of the Hippo Pathway in Non-Cancer Diseases  
Hippo signaling has shown to be important in tissue regeneration. In mice 
treated with dextran sodium sulfate (DSS), a chemical that initiates injury in the 
large intestine and starts the regeneration process, elevated levels of YAP were 
observed (Varelas, X., 2014). In another study, mice that lacked YAP were 
unable to undergo a regenerative response following a DSS induced injury in the 
colon (Cai, J et al., 2010). Another study showed the involvement of YAP in 
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promoting non-dividing cells to enter the cell cycle. The study involved liver and 
heart tissues which are known to have long turnover rates compared to the 
crypts of the large intestine. In mutant MST1/2 mice, there was an unscheduled 
hepatocyte and cardiomyocyte proliferation in adult mice (Song, H et al., 2010). 
These studies indicate that Hippo pathway modulation has the potential to be 
useful in repairing certain tissues that have lost the ability to regenerate as well 
as to augment the repair in certain damaged tissues. Although sustained 
activation of the Hippo pathway may have oncogenic potential in several tissues, 
a transient activation of the Hippo pathway may prove beneficial in several 
instances.  
With the Hippo pathway being implicated in the pathogenesis of several 
diseases, the potential of therapeutically targeting this signaling cascade is 
immense. Several cancers are associated with an increase in levels of YAP and 
TAZ. Directly or indirectly attenuating the activity of these proteins presents a 
logical approach to treating malignancies. However, there are no known small 
molecule inhibitors that turn the Hippo tumor suppressor pathway on to limit the 
amount of YAP and TAZ translocation into the nucleus and regulate organ 
growth. In our study, we developed a simple fluorescence-based readout of 
Hippo pathway activity and used that assay to test several small molecule 
inhibitors for their effects on modulating the Hippo Pathway. 
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Rationale and Specific Aims  
• In many cancers, the Hippo pathway is functionally deregulated or 
“switched off”. We aim to modulate the deregulated Hippo tumor 
suppressor pathway. 
• Small molecule modulators have not been used to target this pathway 
previously. We describe the discovery of two small molecule activators of 
the Hippo pathway.  
• Discovery of a modulator has the potential to turn into translational 
research which can ultimately be used in a clinical setting. 
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MATERIALS AND METHODS 
Cell Lines: Telomerase-immortalized RPE-1 cells were acquired from ATCC and 
cultured in DMEMF12 + 10% FBS at 37° Celsius in 5% humidified CO2.  
HEK 293T17 cells were a generous gift from Dr. Herbert Cohen of Boston 
University School of Medicine and were cultured in DMEM/high glucose + 10% 
FBS in at 37° Celsius in 5% humidified CO2.  
HK-2 cells were a generous gift from Dr. Herbert Cohen of Boston 
University School of Medicine which were cultured in DMEM + 10% FBS at 37° 
Celsius in 5% humidified CO2. 
Immunoblotting 
Protein Collection 
Total cellular protein was collected by washing cells with ice-cold 
Phosphate Buffered Saline (PBS) (Life Technologies, Grand Island, NY) and 
solubilizing extracts in RIPA lysis buffer (50mM Tris-HCl, pH 7.4, 150 mM NaCl, 
0.5% Sodium deoxycholate, 0.1% Sodium Dodecyl Sulfate (SDS)) (Boston 
Bioproducts, Ashland, MA) supplemented with both phosphatase (Boston 
Bioproducts, Ashland, MA) and protease (Boston Bioproducts, Ashland, MA) 
inhibitors. Cells were scraped, collected, and incubated for 10 min on ice. 
Extracts were then centrifuged (17,000g) for 10 min. Supernatant was collected 
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and 4X reducing buffer (Boston Bioproducts, Ashland, MA) was added to the 
sample to make 1X. Finally, the sample was then boiled at 90° Celsius for 5 min.  
Sample running 
Protein samples were loaded onto 7.5% polyacrylamide gels and 
electrophoresed at 120 V for 1.5 h (Bio-rad, Waltham, MA) with running buffer 
(0.025 M Tris base, 0.2 M Glycine, 0.18 M SDS). 
Sample transfer 
Protein extracts run on polyacrylamide gels were transferred to 
Polyvinylidene Fluoride (PVDF) membranes (GE Healthcare, Buckinghamshire, 
UK) using wet transfer (Bio-rad, Waltam, MA) in transfer buffer (0.027 M Tris 
base, 0.25 M Glycine, 20% by volume methanol) for 2 h at 350 mA. 
Subsequently the PVDF membrane was blocked in blocking buffer (5% non-fat 
milk in TBS-Tween (0.02 M Tris, 0.15 M NaCl, 0.2% Tween-20, pH 7.6)) for 1 h 
at room temperature. The membrane was incubated in primary antibody (Cell 
Signalling, Beverly, MA) overnight. PVDF membrane was washed 6 times (5 min 
each) with TBS-Tween and incubated in secondary antibody (GE Healthcare, 
Buckinghamshire, UK) conjugated with horse-radish peroxidase diluted 1:8000 in 
blocking buffer (1% non-fat milk in TBS-Tween). After washing the membrane 6 
times (5 min each) with TBS-Tween, the membrane was incubated with 
chemiluminescent reagent (ECL prime, GE Healthcare, Buckinghamshire, UK) 
for 1 min at room temperature and the chemiluminescent signals were visualized 
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by autoradiography (ChemiDoc Imager, Bio-Rad, Ashland, MA) and analyzed 
using Image Lab software (Hercules, CA). 
Making Polyacrylamide Gels 
To make one gel, 1.4 mL 40% Acrylamide solution (Fisher Bioreagents, 
Fairlawn, NJ), 1.875 mL resolving buffer solution (0.5M Tris base, 0.4% SDS, pH 
6.8), 4.2 mL deionized water, 37.5 µL APS (Ammonium Persulfate) solution 
(Fisher Scientific, Fairlawn, NJ)  (1 g in 10 mL milipore water) and 3.75 µL 
tetramethylenediamine (TEMED) (Fisher Bioreagents , Fairlawn, NJ) were mixed 
and poured into a cast (Bio-rad, Waltham, MA) and left to polymerize. Once 
polymerized, 370 µL 40% acrylamide (Fisher Bioreagents), 0.94 mL stacking 
buffer (1.5 M Tris base, pH 8.8, Fisher Bioreagents), 2.42 mL deionized water, 
18.75 µL APS and 3.75 µL TEMED were mixed then poured into the same cast 
(Bio-rad, Waltham, MA), and a 15-well comb was added on top and the gel was 
left to polymerize. 
Making Phos-tag™ Gels  
To make resolving buffer of one gel, 2.33 mL 40% Acrylamide Solution 
(Fisher Bioreagents), 1.75 mL resolving buffer solution (0.5M Tris base, 0.4% 
SDS, pH 6.8), 0.14 mL of 20 µM Phos-tag solution (Phos-tag acrylamide AAL-
107; NARD Institute, Amagasaki Institute, Japan, Lot# 13J-01), 0.14 mL 10 µM 
MnCl2 solution, 2.52 mL distilled water, 20 µL TEMED (Fisher Bioreagents, ) and 
0.1 mL APS were added together. Once polymerized, 370 µL 40% acrylamide 
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(Fisher Bioreagents), 0.94 mL stacking buffer (1.5 M Tris base, pH 8.8, Fisher 
Bioreagents), 2.42 mL deionized water, 18.75 µL APS and 3.75 µL TEMED were 
mixed then poured into the same cast (Bio-rad, Waltham, MA), and a 15-well 
comb was added on top and the gel was left to settle. 
Immunofluorescence 
For all immunofluorescence experiments, Cells were seeded in 12-well 
plates on glass coverslips overnight and were treated with inhibitors for 1 hour.  
Paraformaldehyde Fixation 
Coverslips were washed with PBS for 1 min and fixed in 4% 
Paraformaldehyde/PBS for 10 min at room temperature. Cells were extracted in 
0.5% Triton/PBS for 5 min and incubated in 5%TBS/BSA for blocking for 30 min 
at room temperature. Following blocking, cells were incubated at room 
temperature in 1:500 dilution of primary antibody (YAP, Santa Cruz 
Biotechnology, Dallas, TX) in blocking buffer. Next, coverslips were washed with 
5% TBS/BSA for 5 min at room temperature and incubated in secondary 
antibody conjugated to a fluorescent dye (Life Technologies, Grand Island, NY) 
for 30 min. Following the secondary antibody incubation, the coverslips were  
washed in 5% TBS/BSA for 5 min and mounted on slides (Fisher Scientific, 
Waltham, MA) using prolong antifade solution (Molecular Probes, Eugene, OR). 
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Glutaraldehyde Fixation 
Coverslips were washed in MTSB for 1 min, extracted in 0.5% 
MTSB/Triton for 2 min followed by a second wash in MTSB for 2 min. Cells were 
fixed in 1% Glutaraldehyde/PBS for 10 min, quenched with 2 washes in NaBH4 
solution for 12 min each, and blocked in 5% TBS/BSA blocking buffer for 30 min. 
Following blocking, cells were incubated in primary antibody (YAP, Santa Cruz 
Biotechnology, Dallas, TX) in blocking buffer for 1 h at room temperature. 
Coverslips were washed in 5% TBS/BSA for 5 min and incubated in secondary 
antibody (Life Technologies, Grand Island, NY). Coverslips were washed in 5% 
TBS/BSA for 5 min and PBS for 5 min before mounting on slides (Fisher 
Scientific, Waltham, MA) using prolong antifade solution (Molecular Probes, 
Eugene, OR). 
Imaging 
Slides were imaged using a Nikon Eclipse Ti inverted epifluorescence 
microscope (Nikon, Melville, NY). Image analysis was performed using NIS-
Elements Software (Melville, NY). 
Small-molecule modulators 
The small molecule modulators were a generous gift from Dr. Nathaniel 
Gray of Harvard Medical School and the Dana-Farber Cancer Institute. 
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RESULTS 
Identification of small molecule modulators of the Hippo pathway 
Initially, we postulated that small molecules that affect Hippo signaling 
may do so by regulating the function of the LATS2 kinase. To identify small 
molecule inhibitors from the library of compounds that would modulate the Hippo 
pathway, the Ambit KinomeSCAN Assay was used. In KinomeSCAN screening, 
the interaction between the test compounds and 450 other kinases is measured. 
We selected compounds (Fig. 2) that showed an interaction with LATS2, a 
known core component of the Hippo pathway. 
Medium throughput screen of potential LATS modulators identifies BX-912 
and AZD 7762 as activators of the Hippo tumor suppressor pathway. 
We were interested in examining how each of the small molecules affect 
the Hippo pathway. The immunofluorescence screen that we performed to detect 
the YAP levels after treatment of each of the modulators showed a decrease in 
nuclear YAP by all of the selected modulators (Fig. 3a) which were quantified 
(Fig. 3b). Out of all the small molecule modulators, AZD 7762 and BX-912 had 
the most robust cytoplasmic retention of YAP, an indicator that the Hippo 
pathway was on. This suggests that these compounds may activate the Hippo 
pathway. Hence, we decided to study AZD 7762 and BX-912 effects in more 
depth.  
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AZD 7762 does not act on Hippo signaling via its canonical members 
As a result of a hit from the previous screen, we were particularly 
interested in determining the mechanism of action of AZD 7762 on the Hippo 
pathway. Besides binding to LATS2 in the kinomeSCAN (Fig. 2), AZD 7762 is 
also a known inhibitor of the C-terminal Src Kinase-homologous Kinase 1 (Chk1) 
and C-terminal Src Kinase-homologous Kinase 2 (Chk2) kinases (Zabduloff, S et 
al., 2008). To compare its impact on YAP localization, we used CHIR 124, 
another known Chk 1 inhibitor which showed a robust retention of YAP 
localization in the cytoplasm (Fig. 5a & 5b). However, siRNA of Chk1 and Chk2 
kinases did not cause modulation on any of the components of the Hippo 
pathway (Lim, S., Personal Communication).  
 
BX-912 activates the Hippo tumor suppressor pathway in a dose dependent 
fashion 
We then analyzed a second molecule, BX-912, that we found to inactivate 
YAP. BX-912 is a known PDK1 inhibitor (Feldman, R et al., 2005). The 
PI3K/PDK1/Akt/mTOR pathway (Fig. 4) is an intracellular pathway that plays a 
key role in cellular proliferation and has been known to be overactive in several 
types of cancers. Activation of Phospoinositide 3-Kinase (PI3K) is achieved by a 
wide variety of ligands which results in phosphorylating Phosphoinositide-
dependent Kinase-1 (PDK1), which phosphorylates Protein Kinase B (Akt) 
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thereby activating it. Activated Akt results in various downstream effects including 
increased proliferation and reduced apoptosis (Engleman, J., 2009). 
5 µM and 10 µM concentration of BX-912 drug treatment in RPE-1 cells 
showed a significant increase in the phospho-YAP to YAP ratio as compared to 
the control visualized by immunoblotting (Fig 6). This was further confirmed by 
performing immunofluorescence staining for YAP localization following drug 
treatment at different doses, the drug treatment resulted in higher cytoplasmic 
retention of YAP at 10 µM treatment of BX-912 (Fig. 7 a & b).  
BX-912 effect on the Hippo pathway remains conserved throughout 
different cell lines 
To further confirm the trends of BX-912 in other cell lines, western blot 
experiments were performed in HK-2 cells (Fig. 8) and HEK293-T cells (Fig. 9). 
Trends similar to RPE-1 were observed in the HK-2 cell line whereas in 
HEK293T there was a significant increase in phospho-YAP to YAP levels only at 
10 µM. This is consistent with the KinomeSCAN results where the concentration 
at which BX-912 interacted with LATS2 was 10 µM.  
BX-912 does not affect actin cytoskeleton integrity of the cell 
Disruption of the actin skeleton results in cytoplasmic retention of YAP 
(Zhao, B et al., 2012). To determine if BX-912 disrupts the actin cytoskeleton of 
the cell which may result in cytoplasmic retention of YAP in the cells, we 
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performed Phalloidin staining on RPE-1 cells following BX-912 10 µM treatment 
(Fig. 10). The results did not show any difference in the actin cytoskeleton 
between the control group and the treated group, indicating that BX-912 does not 
cause activation of the Hippo pathway via actin cytoskeleton disruption.  
BX-912 does not affect Hippo pathway via SAV-1 phosphorylation 
  Salvador-1 (SAV-1) is one of the adaptor proteins that modulates the 
Hippo pathway by forming a complex with PDK1. Phosphorylated SAV-1 then 
phosphorylates the downstream proteins, LATS1/2 and YAP, and ultimately 
controls cell proliferation by retaining YAP into the cytoplasm (Fig. 1a) (Harvey, F 
et al., 2007). To determine if BX-912 treatment results in phosphorylation of SAV-
1 which could result in phosphorylation of LATS or YAP, and in turn exclude YAP 
from nuclear translocations, we performed western blot on Phos-tag gels to 
determine SAV-1 phosphorylation levels (Fig. 11). None of the concentrations of 
BX-912 treatments affected the phosphorylation levels of SAV-1 (Fig. 11a).  Fig. 
11b was reported as a control to show presence of proteins detected by flag 
antibody. 
AZD 7762 has an off-target effect on the PI3K signaling pathway 
Chk 1 and Chk 2 kinases, which are inhibited by AZD 7762, are not known 
to play a direct role in Hippo signaling pathway. To determine if AZD 7762 
affected YAP localization via the PI3K signaling, we looked at the phospho-Akt 
and Akt levels after treatment of varying concentration of AZD 7762. There was a 
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significant decrease in phospho-Akt levels as the concentration of AZD 7762 
increased indicating that the small molecule modulator decreased proliferation of 
the cells by inactivating the PI3 kinase pathway (Fig. 12). This showed that AZD 
7762 caused cytoplasmic retention of YAP by inhibiting the PI3K signaling.  
DISCUSSION 
BX-912 and GSK 233470 
BX-912, a potent PDK1 inhibitor, caused cytoplasmic retention of YAP in 
our screen. To confirm the results, we compared BX-912 with another potent 
PDK1 inhibitor GSK 233470 (Najafor, A et al., 2011). Treatment with GSK 
233470 at various concentrations did not result in exclusion of YAP which was 
observed following drug treatment of BX-912. Both of these results were 
confirmed by another laboratory (Gumbiner, B., personal communication). Their 
treatment of GSK 233470 did not affect YAP localization at lower concentrations 
whereas 10 µM treatment of BX-912 showed a robust increase in cytoplasmic 
retention of YAP. We believe that this discrepancy in results exists because GSK 
233470 is known to be more effective at inhibiting PDK1 substrates that are 
active in the cytosol as compared to those that are at the plasma membrane 
(Najafor, A et al., 2011). The role of PDK1 at the cytoplasm and at the plasma 
membrane was further identified by Kim, S et al., where they discovered that 
blocking the membrane localization of PDK1 inhibits processes such as cellular 
proliferation (2001). This leads us to conclude that when PDK1 is present at the 
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plasma membrane, the cells undergo proliferation and when PDK1 is localized to 
the cytoplasm the cellular proliferation ceases. Since our cells were growing 
normally prior to BX-912 treatment and the fact that we were unable to see the 
similar trends in YAP localization following GSK 233470 treatment, we believe 
that BX-912 might be acting at the plasma membrane.  
BX-912 importance and mechanism 
BX-912 presents as a promising drug for anti-cancer therapy. In several 
cancers that involve the Hippo pathway, it is known that none of the components 
are mutated but instead, the pathway is only deregulated. Therefore, a small 
molecule modulator that can reactivate the Hippo pathway may prove as an 
effective treatment in those cases. However, understanding the mechanism by 
which the drug works is important as it enables us to determine the scenarios in 
which the drug treatment would produce a desired result as well as enable us to 
predict the side effects of the treatment.  
AZD 7762 and CHIR-124  
This study showcases the fact that the Hippo pathway can be modulated 
by several small molecule inhibitors which may work directly or indirectly. AZD 
7762, a known Chk1 kinase inhibitor showed a robust decrease in YAP 
localization in the nucleus following the drug treatment (Zabludoff, S et al., 2008). 
Similar results were also observed in CHIR-124, another Chk1 kinase inhibitor, 
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which is consistent with the results from Tse N et al; they found that CHIR-124 
treatment decreased cell proliferation and caused an increase in apoptosis 
(2007). Even though the studies have predicted AZD 7762 to be promising for 
anti-cancer therapies, clinical trials of the drug have been unsuccessful. In 
patients with solid tumors, AZD 7762 treatment caused bradycardia, 
hypertension and elevated troponin T levels indicating that patients might suffer 
from cardiac tissue damage (Seto, T et al., 2013). These complications remind 
us of the difficulty that arises in anti-cancer therapies where a promising 
treatment has an impact on several other necessary processes which are 
important for normal functioning.  
Future directions 
The promising effects of BX-912 were seen in normal cell lines (RPE-1, 
HK-2 and HEK293T). For us to prove that the drug can be effective for anti-
cancer therapy, we need to test its effectiveness in cancer cell lines. Currently, 
we have only focused on Immunofluorescence studies and protein collection. We 
can further verify the effectiveness of the small molecule modulator by doing 
qPCR following BX-912 treatment in both normal and cancer cells to determine 
the transcript levels of YAP and TAZ target genes. Finally, we can test our drug 
on animal models by using nude mice with a transplanted tumor and see if our 
drug is effective in either decreasing the size of the tumor. 
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Fig 1. Schematic representation of the major components of the Hippo tumor 
suppressor pathway. When the Hippo pathway is “on”, MST1/2 phosphorylate 
Sav 1 and LATS1/2 which then go on to phosphorylate YAP. Phosphorylated 
YAP is retained in the cytoplasm and suppresses gene transcription. When 
the Hippo pathway is “off”, MST1/2 and LATS1/2 are not associated. 
Therefore, they do not phosphorylate YAP as a result YAP translocates into 
the nucleus and promotes the expression of target genes. 
b) Hippo Off 
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Figure 2a. Molecular structures of the small molecule modulators used 
from the library.  Modulators were selected based on the fact that they 
interacted with LATS2 on the Ambit KinomeSCAN. [Modulators and 
KinomeSCAN data was provided by Dr. Nathaniel Gray of Harvard Medical 
School]. 
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Figure 2b. Molecular structures of the small molecule modulators used from 
the library.  Modulators were selected based on the fact that they interacted 
with LATS2 on the Ambit KinomeSCAN. [Modulators and KinomeSCAN data 
was provided by Dr. Nathaniel Gray of Harvard Medical School]. 
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Figure 3a. Localization of endogenous YAP levels were identified using 
immunofluorescence staining in RPE-1 cells following 1 hour treatment of 
small molecule inhibitors (200X). 
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Figure 3b. Endogenous YAP levels were quantified from immunofluorescence 
staining in RPE-1 cells following 1 hour treatment of small molecule modulators. 
25 
 
 
 
 
 
  
Figure 4. Schematic representation of the  PI3K-PDK1-AKT-mTOR pathway. 
Figure Adapted from Cunningham, T & Ruggero, D., 2013. 
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Figure 5a. Localization of endogenous YAP was performed using 
immunofluorescence staining in RPE-1 cells following 1 hour treatment of 
known compounds (200X). 
Control DMSO 1 
Hour 
GSK 233470 10 
µM 1 Hour 
CHIR 124 
10 µM 1 Hour 
BY-719 10 µM 1 
Hour 
AS 605240 
10 µM 1 Hour 
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Figure 5b. Endogenous YAP levels were quantified from immunofluorescence 
staining in RPE-1 cells following 1 hour treatment of known compounds. 
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Figure 6. BX-912 acts in a dose dependent manner in RPE-1 cells. (A) 
Immunoblot showing phospho-YAP, total YAP and loading control (β-actin) 
[Lane 1=Control without BX-912 treatment, lane 2= 1 uM treatment, lane 3= 2 
uM treatment, lane 4= 5 uM treatment and lane 5= 10 uM treatment]. (B) 
Graph showing the ratios of phospho-YAP to total YAP levels. 
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Figure 7a. Localization of endogenous YAP levels were identified at various 
concentrations using immunofluorescence staining in RPE-1 cells following 1 
hour treatment of BX-912 (200X). 
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Figure 7b. Endogenous YAP levels were quantified from immunofluorescence 
staining in RPE-1 cells following 1 hour treatment of small molecule 
modulators at different concentrations. 
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Figure 8. BX-912 acts in 
a dose dependent 
manner in HK-2 cells. 
(A) Immunoblot showing 
the phospho-LATS, total 
LATS, phospho-YAP,  
total YAP, TAZ and 
loading control (α-
tubulin) [Lane 1=Control 
without BX-912 
treatment, lane 2= 1 uM 
treatment, lane 3= 2 uM 
treatment, lane 4= 5 uM 
treatment and lane 5= 
10 uM treatment]. (B) 
Graph showing the 
ratios of phospho-YAP 
to total YAP levels. 
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Figure 9. BX-912 acts in a dose dependent manner in HEK293T cells. (A) 
Immunoblot showing the phospho-LATS, total LATS and loading control (α-
tubulin) [Lane 1=Control without BX-912 treatment, lane 2= 1 uM treatment, 
lane 3= 2 uM treatment, lane 4= 5 uM treatment and lane 5= 10 uM 
treatment]. (B) Graph showing the ratios of phospho-LATS to total LATS 
levels. 
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a) 
Figure 10. BX-912 
does not affect the 
actin cytoskeleton in 
cells. Phalloidin 
staining showing 
the actin 
cytoskeleton in a) 
control cells with 
DMSO treatment 
and b) cells treated 
with 10 µM BX-912 
(200X). 
b) 
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Figure 11. BX-912 
does not affect the 
Hippo pathway via 
SAV-1 
phosphorylation. 
A) Phos-tag gel 
showing the 
phosphorylation 
levels of SAV-1 
following treatment 
with various 
concentration of 
BX-912. Arrow 
indicate the 
predicted motion 
of  the proteins. B) 
Phos-tag blot with 
flag-tag antibody. 
Arrows indicate 
detected proteins 
at different levels. 
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